阿那曲唑
參考文獻

1 2 3 4 5  .   [2024-07-06]. （原始内容存档于2019-07-31）.
1 2 3 4 5 6 7 8 9 10 11 12  Lønning P. . Clinical Pharmacokinetics. 2003, 42 (7): 619–631. PMID 12844324. S2CID 9585901. doi:10.2165/00003088-200342070-00002.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  Lønning P, Pfister C, Martoni A, Zamagni C. . Seminars in Oncology. August 2003, 30 (4 Suppl 14): 23–32. PMID 14513434. doi:10.1016/S0093-7754(03)00305-1.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  Sanford M, Plosker GL. . Drugs. 2008, 68 (9): 1319–1340. PMID 18547136. S2CID 195687223. doi:10.2165/00003495-200868090-00007.
↑  . Chemical Entities of Biological Interest (ChEBI). European Molecular Biology Laboratory.   [2011-08-14]. （原始内容存档于2011-09-22）.
1 2 3 4 5 6 7 8 9 10 11 12 13   (PDF). FDA.   [2019-07-31]. （原始内容存档 (PDF)于2019-07-31）.
1 2 3 4 5 6 7 8 9 10  . The American Society of Health-System Pharmacists.   [2016-12-08]. （原始内容存档于2016-12-21）.
1 2  Fischer J, Ganellin CR. . John Wiley & Sons. 2006: 516. ISBN 9783527607495. （原始内容存档于2016-12-20） （英语）.
1 2  Dukes M. . Oncology. 1997, 54 (2): 6–10. PMID 9394853. doi:10.1159/000227748.
↑  World Health Organization. . Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
↑  . ClinCalc.   [2024-01-14]. （原始内容存档于2024-01-15）.
↑  . ClinCalc.   [2024-01-14]. （原始内容存档于2020-07-05）.
1 2 3  Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. . Lancet. 2005, 365 (9453): 60–62. PMID 15639680. S2CID 8350282. doi:10.1016/S0140-6736(04)17666-6.  Template:Primary-inline
↑   (PDF). FDA. （原始内容存档 (PDF)于2019-07-30）.
↑  Schoelwer M, Eugster EA. . . Endocrine Development 29. 2015: 230–9. ISBN 978-3-318-02788-4. PMC 5345994 . PMID 26680582. doi:10.1159/000438895.
↑  Zacharin M. . . Handbook of Experimental Pharmacology 261. Springer. May 2019: 507–538. ISBN 978-3-030-50493-9. PMID 31144045. S2CID 169040406. doi:10.1007/164_2019_208.
↑  Kliegman RM, Stanton B, St Geme J, Schor NF. . Elsevier Health Sciences. 2015-04-17: 2661–. ISBN 978-0-323-26352-8.
↑  Neyman A, Eugster EA. . Pediatric Endocrinology Reviews. December 2017, 15 (2): 136–141. PMC 5808444 . PMID 29292624. doi:10.17458/per.vol15.2017.nau.treatmentgirlsboys.
↑  Haddad NG, Eugster EA. . . Springer. 2012: 1199–1212. ISBN 978-1-4419-1794-2. doi:10.1007/978-1-4419-1795-9_71.
↑  Haddad NG, Eugster EA. . Best Practice & Research. Clinical Endocrinology & Metabolism. June 2019, 33 (3): 101273. PMID 31027974. S2CID 135410503. doi:10.1016/j.beem.2019.04.007. hdl:1805/19111 .
↑  Misra M, Radovick S. . . Springer. 2018: 589–615. ISBN 978-3-319-73781-2. doi:10.1007/978-3-319-73782-9_26.
↑  Mauras N. . Pediatric Clinics of North America. October 2011, 58 (5): 1167–79, x. PMID 21981954. doi:10.1016/j.pcl.2011.07.007.
↑  Fuqua JS. . The Journal of Clinical Endocrinology and Metabolism. June 2013, 98 (6): 2198–2207. PMID 23515450. doi:10.1210/jc.2013-1024 .
1 2  White R, Bradnam V. . Pharmaceutical Press. 11 March 2015: 108–. ISBN 978-0-85711-162-3.
↑  Simpson ER. . The Journal of Steroid Biochemistry and Molecular Biology. September 2003, 86 (3–5): 225–230. PMID 14623515. S2CID 11210435. doi:10.1016/S0960-0760(03)00360-1.
↑  Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ. . Annals of Oncology. January 2017, 28 (1): 44–56. PMC 7360139 . PMID 28177431. doi:10.1093/annonc/mdw532 .
↑  Russell N, Cheung A, Grossmann M. . Endocrine-Related Cancer. August 2017, 24 (8): R297–R313. PMID 28667081. doi:10.1530/ERC-17-0153 .
1 2  Miyajima M, Kusuhara H, Takahashi K, Takashima T, Hosoya T, Watanabe Y, Sugiyama Y. . Journal of Pharmaceutical Sciences. September 2013, 102 (9): 3309–3319. PMID 23712697. doi:10.1002/jps.23600 .
↑  Thurston DE. . CRC Press. 2006-11-22: 136–. ISBN 978-1-4200-0890-6.
↑  Roy, Kunal. . IGI Global. 2015-02-28: 437–. ISBN 978-1-4666-8137-8.
↑  Smith DA, Allerton C, Kalgutkar AS, van de Waterbeemd H, Walker DK. . John Wiley & Sons. 2012-09-13: 197–. ISBN 978-3-527-64529-9.
↑  . U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Environmental Health Sciences. 1993: 256–260.
↑  Fagerlund A, Cormio L, Palangi L, Lewin R, Santanelli di Pompeo F, Elander A, Selvaggi G. . PLOS ONE. 2015, 10 (8): e0136094. Bibcode:2015PLoSO..1036094F. PMC 4550398 . PMID 26308532. doi:10.1371/journal.pone.0136094 .
↑  Bedognetti D, Rubagotti A, Zoppoli G, Boccardo F. . Journal of Pediatric Endocrinology & Metabolism. 2010, 23 (1–2): 205–206. PMID 20432826. S2CID 41999854. doi:10.1515/JPEM.2010.23.1-2.205.
↑  . Adis Insight.   [2024-07-06]. （原始内容存档于2019-07-31）.
↑  . Adis Insight.   [2024-07-06]. （原始内容存档于2021-08-27）.
1 2  Serefoglu EC, Gokce A, Hellstrom WJ, Guay AT. . . Current Clinical Urology. Humana Press. 2013: 141–147. ISBN 978-1-62703-178-3. doi:10.1007/978-1-62703-179-0_11.
↑  Khera M, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, McCullough A, Morgentaler A, Torres LO, Salonia A. . The Journal of Sexual Medicine. December 2016, 13 (12): 1787–1804. PMID 27914560. doi:10.1016/j.jsxm.2016.10.009.
|  论 编阿斯利康制药 |
| --- | --- |
产品:  阿那曲唑  阿替洛尔  溴苯那敏  布地奈德  度伐利尤单抗  Disufenton sodium  埃索美拉唑  FluMist  吉非替尼  戈舍瑞林  ‎单硝酸异山梨酯  莫维珠单抗  奥美拉唑  帕利珠单抗  丙泊酚  瑞舒伐他汀  罗沙司他  他莫昔芬  替格瑞洛  凡德他尼（英语：）  Vaxzevria  Ximelagatran  佐米曲普坦  利倍卓 
前身和收购:  阿斯特拉公司（英语：）  剑桥抗体科技  MedImmune  捷利康公司  瑞颂制药  亘喜生物 
人物:  Tom McKillop  Louis Schweitzer  苏博科 
 Category:阿斯利康制药